Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Payables (2023 - 2025)

Mangoceuticals' Payables history spans 3 years, with the latest figure at $626964.0 for Q3 2025.

  • For Q3 2025, Payables fell 11.39% year-over-year to $626964.0; the TTM value through Sep 2025 reached $626964.0, down 11.39%, while the annual FY2024 figure was $987501.0, 601.52% up from the prior year.
  • Payables for Q3 2025 was $626964.0 at Mangoceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Payables topped out at $1.3 million in Q2 2025 and bottomed at $30796.0 in Q1 2023.
  • The 3-year median for Payables is $626964.0 (2025), against an average of $545466.8.
  • The largest YoY upside for Payables was 861.78% in 2025 against a maximum downside of 11.39% in 2025.
  • A 3-year view of Payables shows it stood at $140765.0 in 2023, then surged by 601.52% to $987501.0 in 2024, then tumbled by 36.51% to $626964.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Payables are $626964.0 (Q3 2025), $1.3 million (Q2 2025), and $1.2 million (Q1 2025).